Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  Ergomed PLC    ERGO   GB00BN7ZCY67

ERGOMED PLC

(ERGO)
My previous session
Most popular
  Report  
Delayed Quote. Delayed London Stock Exchange - 03/25 12:35:27 pm
166.5 GBp   --.--%
03/11ERGOMED : Christopher Collins
PU
03/01ERGOMED : Rare Disease Day Press Release
AQ
01/24ERGOMED : Board and Management Changes
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed London Stock Exchange
03/19/2019 03/20/2019 03/21/2019 03/22/2019 03/25/2019 Date
167.5(c) 166.5(c) 166.5(c) 166.5(c) 166.5(c) Last
0 111 380 12 675 281 981 13 800 Volume
0.00% -0.60% 0.00% 0.00% 0.00% Change
More quotes
Financials (GBP)
Sales 2018 51,3 M
EBIT 2018 2,30 M
Net income 2018 -1,00 M
Finance 2018 7,00 M
Yield 2018 -
Sales 2019 58,2 M
EBIT 2019 6,00 M
Net income 2019 3,00 M
Finance 2019 9,55 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 1,36x
EV / Sales2019 1,16x
Capitalization 76,8 M
More Financials
Company
Ergomed plc is a provider of drug development services to the pharmaceutical industry. The Company operates through two segments: clinical research services (CRS), and drug safety and medical information services (DS&MI). It provides a range of clinical trial planning, management and monitoring... 
More about the company
Surperformance© ratings of Ergomed PLC
Trading Rating : Investor Rating :
More Ratings
Latest news on ERGOMED PLC
03/11ERGOMED : Christopher Collins
PU
03/01ERGOMED : Rare Disease Day Press Release
AQ
01/24ERGOMED : Board and Management Changes
AQ
01/22ERGOMED : Awarded by the Medicines & Medical Devices Agency of Serbia
AQ
01/17ERGOMED : Congratulates Octapharma on Gaining Marketing Authorisation for Fibryg..
AQ
01/04ERGOMED : Directors' Dealing
PU
2018ERGOMED : issue of shares
PU
2018ERGOMED : Unaudited Interim Results for the six months ended 30 June 2018
AQ
2018ERGOMED : Interim Results
PU
2018ERGOMED : Notice of Interim Results
PU
More news
Analyst Recommendations on ERGOMED PLC
More recommendations
Sector news : Bio Therapeutic Drugs
03/11Regeneron Says FDA Approves Dupixent for Atopic Dermatitis in Adolescents
DJ
03/08Regeneron, Sanofi Get FDA Priority Review for Dupixent
DJ
03/07SHANGHAI RAAS BLOOD PRODUCTS : Spain's Grifols, China's Shanghai RAAS form strat..
RE
03/06GILEAD SCIENCES : Says Once-Daily HIV Regimen Shows Promise in Treating Teens an..
DJ
03/05FDA Approves Controversial Drug for Depression -- Update
DJ
More sector news : Bio Therapeutic Drugs
Chart ERGOMED PLC
Duration : Period :
Ergomed PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ERGOMED PLC
Short TermMid-TermLong Term
TrendsBearishBullishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 2,65  GBP
Spread / Average Target 59%
Managers
NameTitle
Miroslav Reljanovic Executive Chairman
Jan Petracek Chief Operating Officer & Executive Director
Stuart Robert Jackson Chief Financial Officer & Director
Peter Lutz George Senior Independent Non-Executive Director
Christopher Irvin Collins Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ERGOMED PLC6.05%102
GILEAD SCIENCES1.95%81 339
VERTEX PHARMACEUTICALS9.55%46 409
REGENERON PHARMACEUTICALS4.90%42 066
GENMAB8.01%10 747
SAREPTA THERAPEUTICS INC12.03%9 008